Denton Pharma Recalls Ranitidine Tablets Due to NDMA Impurity
Denton Pharma is recalling 467 bottles of Ranitidine Tablets 300 mg because of the presence of NDMA impurity. The affected products were distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves the presence of NDMA, a known carcinogen, which aligns with the rubric criteria for Severe severity (FDA Class II with significant health risks).
Plain-English summary
Denton Pharma, Inc. is recalling 467 bottles of Ranitidine Tablets, USP 300 mg. The affected products are available in 15-count and 90-count bottles and were repackaged by Northwind Pharmaceuticals in North Brenheim, NY. The recall is due to Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of the NDMA impurity in the product.
The recalled products are identified by specific lot codes and expiration dates, including N106851901, N106851902, C106851901, C106851902, C106851903, C106851904, and C106851905. These products were distributed nationwide. The FDA has classified this recall as Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Consumers who have these specific bottles of Ranitidine Tablets should stop using them and contact their healthcare provider or pharmacist for guidance on alternative treatments or returns.
The recalled product
- Product
- Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 90-count bottles (NDC 70934-287-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131
- Manufacturer
- Denton Pharma, Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 467
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- a). N106851901
- Exp. 11/30/2021 N106851902
- Exp. 10/31/2021 b). C106851901
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Denton Pharma, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Denton Pharma, Inc.
See all →- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDenton Pharma Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDenton Pharma Recalls Ranitidine Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-01-29
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11